These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27840914)

  • 21. MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1.
    Lee M; Kim EJ; Jeon MJ
    Oncotarget; 2016 Feb; 7(8):8726-42. PubMed ID: 26646586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
    Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
    FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs.
    Zhang M; Matyunina LV; Walker LD; Chen W; Xiao H; Benigno BB; Wu R; McDonald JF
    Sci Rep; 2017 Aug; 7(1):8171. PubMed ID: 28811560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
    Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
    Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization.
    Smirnoff P; Roiz L; Angelkovitch B; Schwartz B; Shoseyov O
    Cancer; 2006 Dec; 107(12):2760-9. PubMed ID: 17109444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27.
    Acquati F; Morelli C; Cinquetti R; Bianchi MG; Porrini D; Varesco L; Gismondi V; Rocchetti R; Talevi S; Possati L; Magnanini C; Tibiletti MG; Bernasconi B; Daidone MG; Shridhar V; Smith DI; Negrini M; Barbanti-Brodano G; Taramelli R
    Oncogene; 2001 Feb; 20(8):980-8. PubMed ID: 11314033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells.
    Lin Y; Cui M; Xu T; Yu W; Zhang L
    Mol Med Rep; 2014 Jun; 9(6):2499-504. PubMed ID: 24718658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymer-based delivery of RNA-based therapeutics in ovarian cancer.
    Weirauch U; Gutsch D; Höbel S; Aigner A
    Methods Mol Biol; 2013; 1049():443-65. PubMed ID: 23913237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.
    Liu R; Liu F; Li L; Sun M; Chen K
    Biomed Pharmacother; 2015 May; 72():52-7. PubMed ID: 26054675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-661 contributed to cell proliferation of human ovarian cancer cells by repressing INPP5J expression.
    Zhu T; Yuan J; Wang Y; Gong C; Xie Y; Li H
    Biomed Pharmacother; 2015 Oct; 75():123-8. PubMed ID: 26282217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human recombinant RNASET2-induced inflammatory response and connective tissue remodeling in the medicinal leech.
    Baranzini N; Pedrini E; Girardello R; Tettamanti G; de Eguileor M; Taramelli R; Acquati F; Grimaldi A
    Cell Tissue Res; 2017 May; 368(2):337-351. PubMed ID: 28070637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
    Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
    Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2.
    Xia Y; Gao Y
    Biochem Biophys Res Commun; 2014 May; 447(3):446-51. PubMed ID: 24735543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
    Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
    Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.
    Wu H; Xiao Z; Wang K; Liu W; Hao Q
    Biochem Biophys Res Commun; 2013 Nov; 441(4):693-700. PubMed ID: 24157791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.
    Li Y; Xiao M; Guo F
    Tumour Biol; 2017 May; 39(5):1010428317705508. PubMed ID: 28475012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
    Zhang X; Liu J; Zang D; Wu S; Liu A; Zhu J; Wu G; Li J; Jiang L
    Oncotarget; 2015 Jun; 6(17):15180-93. PubMed ID: 25893382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.